Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Receivables - Net: 2019-2021

  • 4D Molecular Therapeutics' Receivables - Net fell 96.84% to $47,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $47,000, marking a year-over-year decrease of 96.84%. This contributed to the annual value of $47,000 for FY2021, which is 96.84% down from last year.
  • As of Q4 2021, 4D Molecular Therapeutics' Receivables - Net stood at $47,000, which was down 94.06% from $791,000 recorded in Q3 2021.
  • Over the past 5 years, 4D Molecular Therapeutics' Receivables - Net peaked at $1.5 million during Q4 2020, and registered a low of $47,000 during Q4 2021.
  • Moreover, its 3-year median value for Receivables - Net was $884,500 (2019), whereas its average is $825,500.
  • Per our database at Business Quant, 4D Molecular Therapeutics' Receivables - Net skyrocketed by 51.94% in 2020 and then tumbled by 96.84% in 2021.
  • 4D Molecular Therapeutics' Receivables - Net (Quarterly) stood at $978,000 in 2019, then skyrocketed by 51.94% to $1.5 million in 2020, then crashed by 96.84% to $47,000 in 2021.
  • Its last three reported values are $47,000 in Q4 2021, $791,000 for Q3 2021, and $1.5 million during Q4 2020.